0000950170-22-005694.txt : 20220414 0000950170-22-005694.hdr.sgml : 20220414 20220414160133 ACCESSION NUMBER: 0000950170-22-005694 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220411 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20220414 DATE AS OF CHANGE: 20220414 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vor Biopharma Inc. CENTRAL INDEX KEY: 0001817229 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39979 FILM NUMBER: 22827194 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 430 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-655-6580 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 430 CITY: CAMBRIDGE STATE: MA ZIP: 02142 8-K 1 vor-20220411.htm 8-K 8-K
false000181722900018172292022-04-112022-04-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_______________________

FORM 8-K

_______________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 11, 2022

_______________________

 

Vor Biopharma Inc.

(Exact name of registrant as specified in its Charter)

_______________________

 

 

 

 

 

 

 

Delaware

 

001-39979

 

81-1591163

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 

100 Cambridgepark Drive

Suite 101

Cambridge, Massachusetts

 

02140

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (617) 655-6580

(Former Name or Former Address, if Changed Since Last Report)

_______________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share

 

VOR

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On April 11, 2022, Vor Biopharma Inc. (the “Company”) and Christopher Slapak, M.D., Chief Medical Officer of the Company, agreed that Dr. Slapak’s employment with the Company will terminate effective May 6, 2022 in connection with Dr. Slapak’s retirement from the Company. In recognition of Dr. Slapak’s service to the Company, the Company has elected to provide Dr. Slapak with severance benefits that are consistent with those contemplated by the Company’s Executive Severance and Change in Control Benefits Plan (the “Severance Plan”). A description of the Severance Plan is included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 14, 2022, and is incorporated herein by reference. The Company and Dr. Slapak intend to enter into a separation agreement memorializing these terms, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

Vor Biopharma Inc.

 

 

 

 

Date: April 14, 2022

 

 

 

By:

 

/s/ Robert Ang

 

 

 

 

 

 

Robert Ang

 

 

 

 

 

 

Chief Executive Officer

 

 EX-101.PRE 2 vor-20220411_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 3 vor-20220411_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Emerging Growth Company Pre-commencement Issuer Tender Offer Entity Address, State or Province Pre-commencement Tender Offer City Area Code Security Exchange Name Document Period End Date Entity Address, Address Line Two Document Type Entity Address, Address Line One Entity Address, Postal Zip Code Entity Registrant Name Entity Address, City or Town Trading Symbol Local Phone Number Title of 12(b) Security Entity Ex Transition Period Written Communications Entity Central Index Key Entity Tax Identification Number Entity File Number Cover [Abstract] Soliciting Material Entity Incorporation, State or Country Code Amendment Flag EX-101.SCH 4 vor-20220411.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Apr. 11, 2022
Cover [Abstract]  
Document Type 8-K
Entity Registrant Name Vor Biopharma Inc.
Amendment Flag false
Entity Central Index Key 0001817229
Document Period End Date Apr. 11, 2022
Entity Incorporation, State or Country Code DE
Entity File Number 001-39979
Entity Tax Identification Number 81-1591163
Entity Address, Address Line One 100 Cambridgepark Drive
Entity Address, Address Line Two Suite 101
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02140
City Area Code 617
Local Phone Number 655-6580
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol VOR
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 6 vor-20220411_htm.xml IDEA: XBRL DOCUMENT 0001817229 2022-04-11 2022-04-11 false 0001817229 8-K 2022-04-11 Vor Biopharma Inc. DE 001-39979 81-1591163 100 Cambridgepark Drive Suite 101 Cambridge MA 02140 617 655-6580 false false false false Common Stock, $0.0001 par value per share VOR NASDAQ true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports vor-20220411.htm vor-20220411.xsd vor-20220411_lab.xml vor-20220411_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vor-20220411.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "vor-20220411.htm" ] }, "labelLink": { "local": [ "vor-20220411_lab.xml" ] }, "presentationLink": { "local": [ "vor-20220411_pre.xml" ] }, "schema": { "local": [ "vor-20220411.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "vor", "nsuri": "http://vorbiopharma.com/20220411", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "vor-20220411.htm", "contextRef": "C_b0ee6867-7bf7-469f-a25f-53a0c6760a3c", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "vor-20220411.htm", "contextRef": "C_b0ee6867-7bf7-469f-a25f-53a0c6760a3c", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vorbiopharma.com/20220411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 13 0000950170-22-005694-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-005694-xbrl.zip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end